Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.

摘要: Research is currently underway worldwide into the development of receptor-specific radiopharmaceuticals for imaging and treatment cancer. The successful clinical radiolabeled somatostatin analogs cancers overexpressing receptors has catalyzed further preclinical investigation other peptides molecular peptide-receptor radiotherapy, including such well-studied peptide vectors as cholecystokinin, neurotensin, bombesin RGD peptides. Within this larger context, article will focus on current status two more recent additions to list targets – guanylate cyclase C, a specific marker colorectal cancer, urokinase plasminogen activator receptor, cell-surface receptor overexpressed in diverse cancer types.